Rethinking Progress in Clinical Trials
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
False
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
October 23, 2026
1 min read
Industry leaders debate the manufacturing, regulatory, financial, and commercial barriers preventing advanced therapies from reaching more patients
October 22, 2026
5 min read
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
October 22, 2026
5 min read
Alcami’s Kerrie Powell, Senior VP of Sales, discusses the challenges of sterile biologics manufacturing and what sponsors should look for in a CDMO partner
October 20, 2026
4 min read
Regeneron Genetics Center’s Luca Lotta explains how population-scale genetic evidence can reveal more promising drug targets and open new possibilities for disease prevention
False
Affiliations:
Specialties:
Areas of Expertise: